IA
BMRN icon

IFP Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

IFP Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$9K – 3828
2018
Q2 		$9K Buy
+100
New +$8.76K ﹤0.01% 2946

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

IFP Advisors's BMRN Position: Q2 2026 in Review

IFP Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 5% in Q2 2026, buying an estimated $5.97K and bringing the position to 2,287 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

IFP Advisors first reported a position in BMRN in Q4 2015 and has held it in 42 quarters since. The position peaked at $272K in Q4 2024. 108 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • IFP Advisors held 2,287 shares of BioMarin Pharmaceuticals worth $131K as of Q2 2026.
  • IFP Advisors bought 109 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5.97K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #1793 holding.
  • IFP Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • IFP Advisors's BioMarin Pharmaceuticals position peaked at $272K in Q4 2024.
  • 108 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.